Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma

Conditions:   Carcinoma of Urinary Tract;   Urethral Carcinoma;   Carcinoma of Ureter;   Carcinoma of Renal PelvisInterventions:   Drug: Docetaxel;   Biological: Ramucirumab DP;   Biological: IMC-18F1Sponsor:   Eli Lilly and CompanyActive, not recruiting - verified March 2015
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials